US Medtechs Won't Rest On Laurels After Excise Tax Victory

The US industry's despair over the medical device sales tax, which for all the world looked destined to be reinstated as of January 2018, turned to relief as last-ditch efforts by US manufacturers finally hit home in Congress in mid-month. Industry's success was largely down to lobbying initiatives inspired by senior officials at AdvaMed, but as that body's chairman Nadim Yared told In Vivo, lessons will be learned to ensure an 11th hour rescue mission is not necessary again in two years' time.

Speaking to In Vivo during MedTech Europe's annual industry forum (January 23-25 2018), Yared's predominant emotion was relief rather than euphoria